Raymond James Reiterates Strong Buy Rating on Apellis Pharmaceuticals (APLS), 'a signal of commitment to and confidence in Syfovre'
Tweet Send to a Friend
Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating and $89.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
